Global Head & Neck Cancer Drugs Market Research Report (2021 to 2026) - by Drug Class, Product, End-user and Region
05 janv. 2022 06h33 HE
|
Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
Global Checkpoint Inhibitors Market (2021 to 2030) - Featuring AstraZeneca, Roche Holding and Pfizer Among Others
07 déc. 2021 06h58 HE
|
Research and Markets
Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. This...
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
01 oct. 2021 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021 Marseille, France, October 1, 2021 – ImCheck Therapeutics today...
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
20 sept. 2021 16h15 HE
|
Aprea Therapeutics
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
17 sept. 2021 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021 First EVICTION data from checkpoint inhibitor-refractory solid tumor...
China Pembrolizumab Market Report 2021: Market Size will Expand in the Future Due to the Increased Numbers of Approved Indications
19 avr. 2021 08h18 HE
|
Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Pembrolizumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. After Pembrolizumab...
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
29 mars 2021 06h53 HE
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
United States Cancer Biosimilar Market Report 2021: $15 Billion Opportunity, Drug Dosage, Price & Clinical Trials Insight to 2026
19 mars 2021 06h43 HE
|
Research and Markets
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's...
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
16 mars 2021 08h00 HE
|
Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...